A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cervical Cancer|Gastric Cancer|Stomach Cancer|Gastroesophageal Junction Cancer|Esophageal Cancer|Hepatocellular Carcinoma|Melanoma|Uveal Melanoma|Merkel Cell Carcinoma|Mesothelioma|MSI|Non-small Cell Lung Cancer|NSCLC|Ovarian Cancer|Squamous Cell Carcinoma of the Head and Neck|Small Cell Lung Cancer|Renal Cell Carcinoma|RCC|Triple-negative Breast Cancer|Urothelial Carcinoma|Mismatch Repair Deficiency
Interventions: DRUG: INCAGN02390
Sponsor: Incyte Corporation